2 March 2017 - - US-based specialty pharmaceutical company Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV) has received the CPNP notification number required to commercialise Zestra in all 28 member countries of the European Union, the company said.

Zestra is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women.

To date, to Innovus Pharma's knowledge, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity.

Zestra is currently exclusively partnered with Orimed Pharma in Canada, Sothema Labs for the Middle East and North Africa, Elis Pharma in Turkey and certain select markets, Oz Biogenics for Myanmar and Vietnam, Biotask in Malaysia, J/H in South Korea and non-exclusively to DanaLife in the alternative markets in select European countries and to PT Laras Bumi Resources, LTD in Hong Kong.

It is currently approved to be marketed and sold in 34 countries worldwide including the United States, Canada, Europe, India, Hong Kong, the United Arab Emirates, the United Kingdom, Morocco, and South Korea.

In addition to the United States, the largest market for Zestra, Innovus Pharma currently generates Zestra revenues from the following markets: Canada, Morocco, certain European countries and Hong Kong.

Approximately 43% of women in the United States age 18 to 59, or 50 m, experience some form of Female Sexual Dysfunction according to a published study. (Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors.